Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CpG DNA and TACE in Hepatocellular Carcinoma
NCT03235167Phase 1Unknown
- Sponsor
- Dalian University
- Start
- Oct 2017
- Primary completion
- Oct 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
01
Overview
Phase 1 trial of CpG DNA in hepatocellular carcinoma (HCC), sponsored by Dalian University. Primary endpoints: Overall Survival at 5 years and Metastasis-Free Survival at 5 years. Status: unknown.
02
Drugs
CpG DNA
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03235167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235167.